Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis.

Adjuvant therapy of melanoma with interferon: lessons of the past decade. J Transl Med (2008) 1.28

Interferons induce CXCR3-cognate chemokine production by human metastatic melanoma. J Immunother (2010) 1.10

Interferon lambda: a new sword in cancer immunotherapy. Clin Dev Immunol (2011) 1.04

Survival of cancer patients treated with mistletoe extract (Iscador): a systematic literature review. BMC Cancer (2009) 1.04

Adjuvant therapy for melanoma. Cancer J (2012) 1.01

Clinical and immunologic basis of interferon therapy in melanoma. Ann N Y Acad Sci (2009) 0.92

Mistletoe Preparation Iscador: Are there Methodological Concerns with Respect to Controlled Clinical Trials? Evid Based Complement Alternat Med (2007) 0.92

Cancer therapy with phytochemicals: evidence from clinical studies. Avicenna J Phytomed (2015) 0.90

Triterpenoids amplify anti-tumoral effects of mistletoe extracts on murine B16.f10 melanoma in vivo. PLoS One (2013) 0.89

Adjuvant immunotherapy of melanoma and development of new approaches using the neoadjuvant approach. Clin Dermatol (2013) 0.81

Adjuvant therapy: melanoma. J Skin Cancer (2011) 0.78

Stage-specific survival and recurrence in patients with cutaneous malignant melanoma in Europe - a systematic review of the literature. Clin Epidemiol (2016) 0.78

IFN-λ cancer immunotherapy: new kid on the block. Immunotherapy (2016) 0.76

Malignant melanoma (non-metastatic). BMJ Clin Evid (2007) 0.75

Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol (2000) 9.70

Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med (1998) 7.48

Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer--Childhood Leukemia Cooperative Group. N Engl J Med (1998) 4.95

Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med (1999) 4.20

Sunscreen use and duration of sun exposure: a double-blind, randomized trial. J Natl Cancer Inst (1999) 3.75

The biology of cell locomotion within three-dimensional extracellular matrix. Cell Mol Life Sci (2000) 3.70

Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer (1999) 3.19

Botulinum toxin for palmar hyperhidrosis. Lancet (1997) 3.17

Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes. J Exp Med (1998) 3.04

High frequencies of naive Melan-A/MART-1-specific CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals. J Exp Med (1999) 2.98

Antigen presentation in extracellular matrix: interactions of T cells with dendritic cells are dynamic, short lived, and sequential. Immunity (2000) 2.93

Allogeneic blood and bone-marrow stem-cell transplantation in haematological malignant diseases: a randomised trial. Lancet (2000) 2.72

Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. J Immunol (1998) 2.68

Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. J Clin Oncol (1996) 2.61

Chromosomal gains and losses in primary cutaneous melanomas detected by comparative genomic hybridization. Cancer Res (1998) 2.44

On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group. J Clin Oncol (1989) 2.43

Monoclonal antibody PAL-E specific for endothelium. Lab Invest (1985) 2.37

Clinical relevance of melanoma micrometastases (<0.1 mm) in sentinel nodes: are these nodes to be considered negative? Ann Oncol (2006) 2.30

Quality assessment by expert opinion in melanoma pathology: experience of the pathology panel of the Dutch Melanoma Working Party. J Pathol (1997) 2.28

Epidemiology of invasive cutaneous melanoma. Ann Oncol (2009) 2.21

BRAF mutation testing algorithm for vemurafenib treatment in melanoma: recommendations from an expert panel. Br J Dermatol (2013) 2.17

Chemokines IL-8, GROalpha, MCP-1, IP-10, and Mig are sequentially and differentially expressed during phase-specific infiltration of leukocyte subsets in human wound healing. Am J Pathol (1998) 2.09

[Guideline 'Melanoma' (3rd revision)]. Ned Tijdschr Geneeskd (2005) 2.08

Nicotine, alcohol and drug dependence and psychiatric comorbidity. Results of a national household survey. Br J Psychiatry (2001) 2.01

Monoclonal antibody G 250 recognizes a determinant present in renal-cell carcinoma and absent from normal kidney. Int J Cancer (1986) 1.95

Methadone treatment practices and outcome for opiate addicts treated in drug clinics and in general practice: results from the National Treatment Outcome Research Study. Br J Gen Pract (1999) 1.95

[Long-term results of the multidisciplinary surgical treatment of non-small-cell bronchial carcinoma in the superior sulcus (Pancoast tumour): a retrospective study]. Ned Tijdschr Geneeskd (2007) 1.93

Modulation of multidrug-resistant multiple myeloma by cyclosporin. The Leukaemia Group of the EORTC and the HOVON. Lancet (1992) 1.92

Requirement for the synergy site for cell adhesion to fibronectin depends on the activation state of integrin alpha 5 beta 1. J Biol Chem (1995) 1.91

Preseason hamstring muscle weakness associated with hamstring muscle injury in Australian footballers. Am J Sports Med (1997) 1.90

Cell type heterogeneity of cytokeratin expression in complex epithelia and carcinomas as demonstrated by monoclonal antibodies specific for cytokeratins nos. 4 and 13. Exp Cell Res (1986) 1.90

Cell migration strategies in 3-D extracellular matrix: differences in morphology, cell matrix interactions, and integrin function. Microsc Res Tech (1998) 1.86

T cell-mediated Fas-induced keratinocyte apoptosis plays a key pathogenetic role in eczematous dermatitis. J Clin Invest (2000) 1.85

Matrix metalloproteinases in human melanoma. J Invest Dermatol (2000) 1.84

Serum levels of autoantibodies to BP180 correlate with disease activity in patients with bullous pemphigoid. Arch Dermatol (2000) 1.82

Expression of MAGE genes in primary and metastatic cutaneous melanoma. Int J Cancer (1995) 1.81

Amoeboid leukocyte crawling through extracellular matrix: lessons from the Dictyostelium paradigm of cell movement. J Leukoc Biol (2001) 1.78

Understanding reasons for drug use amongst young people: a functional perspective. Health Educ Res (2001) 1.77

A monoclonal antibody to a differentiation antigen present on mature human macrophages and absent from monocytes. J Immunol (1985) 1.76

Hailey-Hailey disease. Eradication by dermabrasion. Arch Dermatol (1994) 1.73

c-myc down-regulates class I HLA expression in human melanomas. EMBO J (1988) 1.72

Outcomes after methadone maintenance and methadone reduction treatments: two-year follow-up results from the National Treatment Outcome Research Study. Drug Alcohol Depend (2001) 1.70

Antiperinuclear factor, a marker autoantibody for rheumatoid arthritis: colocalisation of the perinuclear factor and profilaggrin. Ann Rheum Dis (1991) 1.68

Gene amplifications characterize acral melanoma and permit the detection of occult tumor cells in the surrounding skin. Cancer Res (2000) 1.67

Expression of the high molecular weight melanoma-associated antigen by pericytes during angiogenesis in tumors and in healing wounds. Am J Pathol (1990) 1.66

Lack of clinical efficacy of imatinib in metastatic melanoma. Br J Cancer (2005) 1.66

Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival. Ann Oncol (2013) 1.65

Contralateral recurrence and prognostic factors in familial non-BRCA1/2-associated breast cancer. Br J Surg (2006) 1.65

Histological grade heterogeneity in multifocal prostate cancer. Biological and clinical implications. J Pathol (1996) 1.64

Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma. Ann Oncol (2014) 1.63

Differential expression of markers for endothelial cells, pericytes, and basal lamina in the microvasculature of tumors and granulation tissue. Am J Pathol (1991) 1.63

N-ras mutations in human cutaneous melanoma from sun-exposed body sites. Mol Cell Biol (1989) 1.61

Aggressive angiomyxoma: multimodality treatments can avoid mutilating surgery. Eur J Surg Oncol (2006) 1.61

A monoclonal antibody specific for cells of the melanocyte lineage. Am J Pathol (1988) 1.60

Erythropoietin depletion and anaemia in diabetes mellitus. Diabet Med (1999) 1.59

Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients. Cancer Res (2001) 1.59

Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1- and non-BRCA1/2 families as compared to sporadic breast cancer cases. Eur J Cancer (2007) 1.58

Expression of gp100, MART-1, tyrosinase, and S100 in paraffin-embedded primary melanomas and locoregional, lymph node, and visceral metastases: implications for diagnosis and immunotherapy. A study conducted by the EORTC Melanoma Cooperative Group. J Pathol (2001) 1.57

Multivariable analysis comparing outcome after sentinel node biopsy or therapeutic lymph node dissection in patients with melanoma. Br J Surg (2007) 1.57

Aneurysmal bone cysts: a clinicopathological study of 105 cases. Cancer (1977) 1.56

Melanocytes as "sensory" and regulatory cells in the epidermis. J Theor Biol (1993) 1.55

NOTCH1 and FBXW7 mutations have a favorable impact on early response to treatment, but not on outcome, in children with T-cell acute lymphoblastic leukemia (T-ALL) treated on EORTC trials 58881 and 58951. Leukemia (2010) 1.54

Angiogenesis in brain tumors; pathobiological and clinical aspects. J Neurooncol (1997) 1.53

Distribution of cytokeratin polypeptides in human transitional cell carcinomas, with special emphasis on changing expression patterns during tumor progression. Am J Pathol (1990) 1.53

Antiphospholipid syndrome associated with immunotherapy for patients with melanoma. Cancer (1994) 1.53

Palliative isolated limb perfusion for advanced limb disease in stage IV melanoma patients. J Surg Oncol (2005) 1.52

Melanocyte lineage-specific antigens recognized by monoclonal antibodies NKI-beteb, HMB-50, and HMB-45 are encoded by a single cDNA. Am J Pathol (1993) 1.51

Regulation of tumor necrosis factor-related apoptosis-inducing ligand sensitivity in primary and transformed human keratinocytes. Cancer Res (2000) 1.51

Prognostic factors for survival and factors associated with long-term remission in patients with advanced melanoma receiving cytokine-based treatments: second analysis of a randomised EORTC Melanoma Group trial comparing interferon-alpha2a (IFNalpha) and interleukin 2 (IL-2) with or without cisplatin. Eur J Cancer (2002) 1.51

Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. Ann Surg (1996) 1.51

Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS. Blood (2001) 1.48

Coexpression of intermediate filament polypeptides in human fetal and adult tissues. Lab Invest (1987) 1.48

Updated IMS recommendations on postmenopausal hormone therapy and preventive strategies for midlife health. Climacteric (2011) 1.47

Naturally occurring human lymphocyte antigen-A2 restricted CD8+ T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients. Cancer Res (2000) 1.47

Granulocyte-macrophage colony-stimulating factor associated with induction treatment of acute myelogenous leukemia: a randomized trial by the European Organization for Research and Treatment of Cancer Leukemia Cooperative Group. J Clin Oncol (1996) 1.47

Hypoxia-induced up-regulation of angiogenin in human malignant melanoma. Cancer Res (1999) 1.46

Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients. J Clin Oncol (1998) 1.46

Safety and efficacy of isolated limb perfusion in elderly melanoma patients. Ann Surg Oncol (2002) 1.46

Human mast cells produce IL-8. J Immunol (1993) 1.44

Should elective lymph node dissection be used for treatment of primary melanoma? J Cancer Res Clin Oncol (1989) 1.44

Clinical phase II study of pegylated liposomal doxorubicin as second-line treatment in disseminated melanoma. Onkologie (2004) 1.43

Influence of opioid choice on mechanical ventilation duration and ICU length of stay. Minerva Anestesiol (2011) 1.43

Tumor progression in human malignant melanoma: five stages defined by their antigenic phenotypes. Int J Cancer (1987) 1.41

[Oncoplastic surgery of the breast: a combination of oncological and plastic surgery]. Ned Tijdschr Geneeskd (2007) 1.40

Expression of interleukin-8 detected by in situ hybridization correlates with worse prognosis in primary cutaneous melanoma. J Pathol (1999) 1.40

Treatment of acute myelogenous leukemia. An EBMT-EORTC retrospective analysis of chemotherapy versus allogeneic or autologous bone marrow transplantation. Eur J Cancer Clin Oncol (1989) 1.40

Immunohistochemical analysis of integrin alpha vbeta3 expression on tumor-associated vessels of human carcinomas. Int J Cancer (1997) 1.40

Clinical evaluation of in vitro chemosensitivity testing: the example of uveal melanoma. J Cancer Res Clin Oncol (2004) 1.39

The effects of negative regional lymph-node dissection on survival and disease-free interval of patients with stage-I malignant melanoma. Neth J Surg (1990) 1.39

Early and extensive contribution of pericytes/vascular smooth muscle cells to microvascular proliferation in glioblastoma multiforme: an immuno-light and immuno-electron microscopic study. J Neuropathol Exp Neurol (1995) 1.39

Induction of alpha-smooth muscle actin expression in cultured human brain pericytes by transforming growth factor-beta 1. Am J Pathol (1994) 1.38

The AJCC staging proposal for cutaneous melanoma: comments by the EORTC Melanoma Group. Ann Oncol (2001) 1.38

TERT promoter mutations in ocular melanoma distinguish between conjunctival and uveal tumours. Br J Cancer (2013) 1.38

Anorectal melanoma: surgical management guidelines according to tumour thickness. Br J Cancer (2003) 1.37

Histopathologic findings in explanted heart tissue from patients with end-stage idiopathic dilated cardiomyopathy. Transpl Int (2001) 1.37

Lymphangiogenesis in malignant tumours: Does it occur? J Pathol (2001) 1.37